Evaluation of local tumor residue after percutaneous radiofrequency ablation therapy for hepatocellular carcinoma
Department of Gastroenterology, Yokohama Minami Kyosai Hospital, Yokohama, Japan; Department of Gastroenterology, Omori Red Cross Hospital, Tokyo, Japan
Department of Gastroenterology, Omori Red Cross Hospital, Tokyo, Japan.
Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
Turk J Gastroenterol ; : -
This article was viewed 0 times, downloaded 1 times
Key Words: Hepatocellular carcinoma, computed tomography, radiofrequency ablation, Sonazoid, CO2-enhanced ultrasonography
Background/Aims: This study’s purpose was to compare the efficacy of CO2-enhanced ultrasonography (US) with that of Sonazoid-enhanced US and conventional US in detecting local tumor residue after percutaneous radiofrequency (RF) ablation therapy for hepatocellular carcinoma.
Materials and Methods: Between February 2009 and March 2010, 141 lesions of 121 hepatocellular carcinoma patients were treated by percutaneous RF ablation, and 22 tumor residues were detected in 22 patients by contrast-enhanced computed tomography. These 22 patients were examined by conventional US, Sonazoid-enhanced US (0.5 mL/body of Sonazoid, intravenous administration), and CO2-enhanced US (10 mL of CO2, hepatic arterial administration).
Results: Tumor residue was confirmed by CO2-enhanced US in all the 22 patients (sensitivity: 100%) in 19 of the 22 patients by Sonazoid-enhanced US (sensitivity: 86%; 3 lesions that were not detected by this modality were located deeper than the sonographic depth (p=0.0109)), and in 17 of the 22 patients by conventional US (sensitivity: 77%; 5 lesions that were not detected by this modality were smaller in terms of the sonographic tumor size (p=0.0278)).
Conclusion: Although CO2-enhanced US requires angiography, it was superior to both Sonazoid-enhanced US and conventional US for detecting tumor residues, particularly deep-seated ones, after percutaneous RF ablation.